ABSTRACT
To identify the role of Interleukin-I Beta[IL- I beta] in patients undergoing intracytoplasmic sperm injection. The quasi-experimental study was conducted at an infertility clinic in Islamabad from June 2010 to August 2011, and comprised couples opting for intracytoplasmic sperm injection. Down regulation of ovaries was followed by calculated stimulation, ovulation induction, oocytes retrieval, intracytoplasmic sperm injection, in vitro maturation of embryos and embryo transfer. Serum Interleukin-I Beta was measured by enzyme-linked immunosorbent assay onovulation induction day. Patients were grouped as non-pregnant with beta human chorionic gonadotropin 5-25 mIU/ml, pre-clinical abortion; beta human chorionic gonadotropin >25 mIU/ml with no cardiac activity and clinical pregnancy with foetal heart confirmation by trans-vaginal scan after 4 weeks of transfer. SPSS 15 was used for statistical analysis. Of the total 323 patients initially registered, embryo transfer could be carried out in 282[87.30%]. Clinical pregnancy was achieved in 101[36%] patients, clinical abortions was the result in 61[22%] cases, while 120[42%] subjects did not conceive at all. Clinical pregnancy was achieved in subjects with high mean Interleukin-I Beta levels; 155.84 +/- 51.65 compared to 41.81 +/- 11.77and 118.46 +/- 35.62pg/mlin non-pregnant, preclinical abortion groups respectively [p=0.001]. The production of Interleukin-I Beta was associated with oocyte maturation, fertilisation, endometrial receptivity and implantation in patients undergoing intracytoplasmic sperm injection
Subject(s)
Humans , Female , Fertilization , Sperm Injections, IntracytoplasmicABSTRACT
Cinnamomum cassia is widely utilized as a spice in different cookeries worldwide, especially in Asian cuisines. This herb is also being used in different forms of traditional medicine [Unani, Ayurvedic, Japanese and Chinese] for managing conditions like dyspepsia, peptic ulcer disease and ischemic brain injury. Recent studies have shown the scientific evidence for the medicinal use of this particular herb in several diseases like H. pylori infection, diabetes, brain ischemia and cancers. This article reviews the literature on potential benefits of the herb published within the last 10 years. The authors used Medical Subject Headings [MeSH] terms [Cinnamomum] with [cassia] or [arromaticum] to filter the PubMed database. To date, no systemic review focusing on medicinal use of C. cassia was found in the literature. Various research articles elucidating diverse pharmacological properties of C. cassia were identified. The standardised extract of C. cassia or the active compounds extracted from the herb might prove to be a novel candidate for early prevention and complimentary management of conditions like diabetes mellitus or H. Pylori-associated disorders
ABSTRACT
Hepatitis C is the disease of liver caused by hepatitis C virus [HCV]. Due to its widespread impact on human population, there is continued surge for new therapeutic agents to treat and reduce HCV. Hence, nowadays HCV is considered as global burden throughout the world. Advancements in therapeutic invention and clinical outcomes are dependent on HCV genome and diversity in nature, pathogenesis, dietary factors, social, economic and environmental factors. In this review we have focused mainly on HCV genome, its history and clinical outcomes from its discovery to present day research. In this article the authors have reviewed the published data from year 1997 to 2014. The topics of main concerns were hepatitis C with diverse nature and recent advances in the treatment of chronic hepatitis C. The authors used MeSH terms "Hepatitis C Virus [HCV]", recent advances in the treatment of "HCV", "HCV and Immunity", "vaccination", or "Interferon therapy" to search the PubMed database. All relevant studies identified were included and are described according to the subheadings. Recent advancement in molecular biology and experimental techniques has opened new insights into the pathophysiology of HCV which is helping in combating this life threatening disease. Although the response to current treatment regimen for HCV is improved however complete recovery from the disease is still a challenge which requires more extensive studies from basic science research to large multicenter clinical trials